PEG-somatropin
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT03255694 | May 2017 → Jun 2030 expected | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03221088 | Jun 2015 → Dec 2018 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02375620 | Apr 2015 → Dec 2023 overdue | fetal growth restriction | Changchun GeneScience Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06024967 | Dec 2023 → May 2025 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01495468 | Mar 2007 → Jan 2008 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT03290235 | Mar 2017 → Oct 2020 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02976675 | Jan 2015 → Jun 2017 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03249480 | Jan 2015 → Aug 2017 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02380235 | Dec 2014 → Jun 2017 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02314676 | Nov 2014 → Jul 2017 | pituitary dwarfism | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02908958 | Nov 2014 → Jun 2017 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG Somatropin | “To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period” NCT03290235 ↗15“Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children” NCT02314676 ↗ “Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency” NCT03249480 ↗ “Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency” NCT02976675 ↗ “Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature” NCT02375620 ↗ “PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.” NCT03221088 ↗ “Pegylated Somatropin (PEG Somatropin)” NCT02380235 ↗ |
| Known as | Jintrolong | “Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with growth hormone...” PMID 36034802 ↗ Aug 20221“Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.” PMID 28566441 ↗ May 2017 |
| Known as | PEG Somatropin Injection | “To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency” NCT02976675 ↗ |
| Known as | PEG-rhGH | “Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with growth hormone...” PMID 36034802 ↗ Aug 20223“We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD).” PMID 28566441 ↗ May 2017 “PEGylated-recombinant human growth hormone (PEG-rhGH) in these children.” PMID 39513569 ↗ Nov 2024 “pegylated recombinant human growth hormone (PEG-rhGH) injection” NCT03221088 ↗ |
| Known as | Pegylated somatropin | “Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children” NCT02314676 ↗3“Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency” NCT02976675 ↗ “Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature” NCT02375620 ↗ “Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit” NCT03290235 ↗ |
| Known as | PEGylated-recombinant human growth hormone | “PEGylated-recombinant human growth hormone (PEG-rhGH) in these children.” PMID 39513569 ↗ Nov 2024 |
| Modality | Protein / enzyme biologic | “Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.” PMID 28566441 ↗ May 2017 |
| Route | Subcutaneous | “patients were randomised 1:1 to receive subcutaneous injections of PEG-rhGH at 0.1 mg/kg/week (low dose) or 0.2 mg/kg/week (high dose) for 52 weeks.” PMID 39513569 ↗ Nov 2024 |